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ABSTRACT
Understanding the implications of cardiovas-
cular (CV) outcomes data of glucose-lowering
agents on the management of type 2 diabetes
mellitus can be challenging for many primary
practitioners. Amongst different classes of dia-
betes medications assessed for CV safety, several
agents within the sodium-glucose transport
protein-2 inhibitor and glucagon-like peptide-1
receptor agonists classes have demonstrated CV
risk reduction. Applying the trial findings to
patients typically seen in clinical practice, such
as those with established CV disease and those
with multiple CV risk factors without estab-
lished CV disease, requires further clarity. To
bridge this gap in our current knowledge, the
aim of this review was to utilise expert-driven
opinions on common case scenarios and prac-
tical recommendations on the most appropriate
choice of agents, according to an individual
patient’s clinical risk profile (CV and kidney
disease), treatment preference and reimburse-
ment environment from an Australian
perspective.
Funding: Boehringer Ingelheim Australia.
Keywords: Cardiovascular; DPP-IV inhibitor;
GLP-1RAs; Hospitalisation; Kidney; MACE;
Management; Outcome; Risk; SGLT-2
inhibitors; Type 2 diabetes
CLINICAL BURDEN OF DIABETES
IN AUSTRALIA
As the worldwide prevalence of type 2 diabetes
mellitus (T2DM) increases, with approximately
8.8% of the adult population (20–79 years of
age) affected, 1.5 million Australians are cur-
rently estimated to have T2DM [1, 2]; it remains
one of the most common chronic conditions
managed in primary care and the number of
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patients with T2DM is estimated to continue to
rise. Indeed,[1 in 10 patients aged 45–64 years
who present to primary practice have been
diagnosed with T2DM and typically have 9
primary practitioner visits a year, 4 of which are
related to diabetes [3]. Most of these individuals
are also diagnosed with other chronic condi-
tions, such as arthritis, depression and notably
cardiovascular disease (CVD), including heart
failure [4], and have associated risk factors of
hypertension and dyslipidaemia. Collectively,
all serve to increase the clinical burden of T2DM
further [5].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
IDENTIFYING CARDIOVASCULAR
RISK IN T2DM IN PRIMARY
PRACTICE
In Australia, as many as two in three adults with
T2DM have CVD [2]. Indeed, CVD is a major
cause of death in these individuals [6]. This
clinical burden makes it imperative that pri-
mary practitioners attempt to reduce the CV
risk of patients with T2DM with agents that
have evidence to improve CV outcomes.
The risk of CV morbidity and mortality is
disproportionately higher in those with T2DM
than in those without [7]. While T2DM was
considered to be ‘‘cardiovascular risk equiva-
lent’’ to those without T2DM but who had
experienced a prior coronary event [8], a more
contemporary view is that there is large
heterogeneity in CV risk among T2DM popula-
tions [9, 10]. Special populations such as
smokers, the elderly, Aboriginal and Torres
Strait Islanders, those of Asian and Pacific des-
cent and those with chronic kidney disease
(CKD) have a higher absolute risk of CVD.
Women and younger adults with diabetes have
a disproportionately higher relative risk of CVD
compared with those without diabetes;
furthermore, those who have T2DM and pre-
existing CVD have a much higher risk of CV
death compared with those with T2DM who do
not already have CVD [11].
Consequently, guidelines recommend CV risk
stratification of patients into one of three cate-
gories—low (\10%), moderate (10–15%) and high
([15%)—to better identify those who would
benefit from a more or less intensive prevention
and management strategy [12]. For Australian
clinicians, for information on how to calculate the
absolute CV risk, refer to the National Vascular
Disease Prevention Alliance initiative at: https://
www.cvdcheck.org.au where you can access the
calculator and supporting resources.
MODIFYING CARDIOVASCULAR
RISK IN T2DM
Is Glycaemic Control Important in CV
Risk?
There are compelling and established data sup-
porting the benefit of long-term glycaemic
control in reducing the risk of microvascular
complications in T2DM. Whether lowering
blood glucose translates into similar macrovas-
cular CV benefits has been a major focus in the
past decade. Studies, such as the United King-
dom Prospective Diabetes Study (UKPDS) and
the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and
Complications (DCCT-EDIC), suggested a ‘le-
gacy effect’ in newly diagnosed individuals with
diabetes, whereby good glycaemic management
improved longer-term CV outcomes [13, 14].
However, other studies, such as Action in Dia-
betes and Vascular Disease (ADVANCE), Action
to Control Cardiovascular Risk in Diabetes
(ACCORD) and Veterans Affairs Diabetes Trial
(VADT) found that intensive glycaemic lower-
ing did not result in favourable CV outcomes
and rather, in some cases, increased the risk of
both total mortality and CV death [15–17].
The potential risks of intensive glucose-low-
ering are further supported by two separate
meta-analyses of CV outcome trials (CVOT) in
T2DM [18, 19]. While both report a modest and
significant reduction in major CV events, such
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as MI, following tighter glycaemic control, they
found that the CV benefit was at the expense of
a significant increase in hypoglycaemia events
and no mortality benefit. Collectively, these
data present a reminder that patient character-
istics, particularly duration of diabetes, and the
‘legacy effect’ may influence the choice of an
individual’s glycated haemoglobin (HbA1c) tar-
get and that this target in turn may change with
long-term, optimal glycaemic control in
advancing diabetes.
Australian Diabetes Society guidelines rec-
ommend an HbA1c target of 7% (53 mmol/mol)
for most T2DM patients [20]. A more stringent
HbA1c target of 6.5% (48 mmol/mol) may be
considered if it can be achieved without hypo-
glycaemia except where contraindications exist
such as known CVD, long duration of T2DM
and if having existing episodes of severe hypo-
glycaemia. For women planning pregnancy, the
goal is to achieve an HbA1c target of 6.0%
(42 mmol/mol). Less ambitious targets are rec-
ommended for elderly patients and those with
lowered awareness of hypoglycaemia or major
comorbidities (HbA1c of 8.0%; 64 mmol/mol)
[20]. For patients with limited life expectancy or
at a palliative care stage, there are no targets and
the goal is to keep them ‘safe’ and relatively
asymptomatic.
Can the Choice of Glucose-Lowering
Medication Impact CV Outcome?
Metformin has been established as baseline
therapy for type 2 diabetes, based on evidence
for a role in the reduction of microvascular
complications from the seminal UKPDS study
and an emergent macrovascular benefit on
long-term analysis [21]. Unlike newer agents,
funded CV outcome trails of similar quality do
not exist, however, as it has been used for
C 60 years in clinical practice, confidence exists
that it certainly does not increase CV risk and,
based upon on the extended data from UKPDS
(in a small cohort of obese patients), is likely to
benefit CVD outcomes [22].
In the case of sulphonylureas, their associa-
tion with CV risk factors, hypoglycaemia and
weight gain is widely recognised [23]. However,
controversy exists with respect to their associa-
tion with CV outcomes and mortality, espe-
cially in patients with an elevated risk of CVD or
established CVD. While observations of
increased CVD events and raised mortality have
questioned the use of sulphonylureas either as
monotherapy or in combination with met-
formin vs. other glucose-lowering agents
[24–27], some meta-analyses and systematic
reviews have provided reassurance on the CV
safety of this drug class [28, 29], alongside the
ADVANCE study [15], and the recent
announcement of the non-inferiority results of
the CAROLINA study [30]. Despite this, with
more favourable CV profiles of newer agents
emerging, ADA/EASD guidelines have shifted
away from recommending the early use of
sulphonylureas in patients with established
CVD [31].
The impact of more recent glucose-lowering
agents on CVD risk had, until recently, been less
well known [32, 33]. There is now increasing
evidence from CVOTs that demonstrates CV
benefits with certain diabetes medications, in
particular the sodium-glucose transport protein-
2 (SGLT-2) inhibitors and glucagon-like pep-
tide-1 receptor agonists (GLP-1RAs) [34]. In
recognition of these findings, there has been a
contemporary shift in the recommended strat-
egy for CV risk reduction in managing T2DM
that extends beyond glucose control.
A summary of recommendations from Aus-
tralian as well as several international guideli-
nes is outlined in BOX 1 [31, 34–38].
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A REVIEW OF THE EVIDENCE
In 2008, the FDA issued a mandate requiring all
new glucose-lowering medications to
demonstrate CV safety prior to approval [32].
Consequently, there are now a multitude of
completed and ongoing CVOTs (Table 1) [34],
particularly for the dipeptidyl peptidase-IV
Box 1: Multifactorial approach to CV risk reduction in T2DM
Approach Guideline target/individualised goal recommendations
HbA1c control HbA1c B 7% (53 mmol/mol)*
*Target customised according to age and comorbidities
Blood pressure control \ 140/90 mmHg for patients with T2DM and hypertension
\ 130/80 mmHg for patients with albuminuria/proteinuria
Measure at every routine visit and on separate days to diagnose and confirm hypertension
Cholesterol management Total cholesterol\ 4.0 mmol/l
HDL-C C1.0 mmol/l
LDL-C\ 2.0 mmol/l (\ 1.8 mmol/l if CVD is present)
Triglycerides\ 2.0 mmol/l*
Assess cholesterol levels at time of T2DM diagnosis, at initial review and every 5 years if
\ 40 years or more frequently if indicated
Assess cholesterol levels at time of statin or initiation of other cholesterol-lowering therapy at
4–12 weeks after initiation or a change in dose and then annually to help monitor response
and adherence to medication
*Note: Canadian guidelines on dyslipidaemia in T2DM stipulate a target of triglyceride
\ 1.5 mmol/l [35]
Therapies with proven CV
benefit
Blood pressure medications (ACEi/ARB favoured if evidence of CKD)
Cholesterol-lowering agents—statin, ezetimibe, PCSK9 inhibitors
Antiplatelet agents—low-dose aspirin (in established CVD)
Glucose-lowering therapies—SGLT-2 inhibitors and GLP-1RAs
Screening for
complications
Cardiac—ECG, longer term monitoring or opportunistic screening may be needed if a patient
is[ 65 years or has a detectable dysrhythmia or is symptomatic [38]
Kidney—assess eGFR and ACR annually, or more frequently if indicated
Eye disease—refer for retinal examination every 2 years (once a year if T2DM[ 15 years or
HBA1c[ 8%, presence of diabetes complications or poorly controlled BP and lipids)
Foot—assess monofilament/vibration annually or more frequently if indicated
Lifestyle interventions Smoking cessation—0 cigarettes/day
Exercise—approximately 30 min of moderate physical activity on most if not all days of the
week (total C150 min/week)
Alcohol consumption—B 2 standard drinks (20 g) per day for men and women
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Table 1 CVOTs of glucose-lowering medications. Adapted from Cefalu et al. [34]
Drug class Cardiovascular outcome trial Completed Ongoing
a-Glucosidase inhibitor
Acarbose Acarbose Cardiovascular Evaluation (ACE) 4
DPP-IV Inhibitor
Alogliptin Examination of Cardiovascular Outcomes with
Alogliptin versus Standard of Care (EXAMINE)
4
Linagliptin Cardiovascular and Renal Microvascular Outcome Study
with Linagliptin in Patients with Type 2 Diabetes
Mellitus (CARMELINA)
4
Cardiovascular Outcome Trial of Linagliptin versus
Glimepiride in Type 2 Diabetes (CAROLINA)
4
Saxagliptin Saxagliptin Assessment of Vascular Outcomes Recorded
in Patients with Diabetes Mellitus–Thrombolysis in
Myocardial Infarction (SAVOR-TIMI 53)
4
Sitagliptin Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS)
4
GLP-1 receptor agonist
Albiglutide Effect of Albiglutide, When Added to Standard Blood
Glucose Lowering Therapies, on Major Cardiovascular
Events in Subjects With Type 2 Diabetes Mellitus
(HARMONY)
4
Exenatide Exenatide Study of Cardiovascular Event Lowering
(EXSCEL)
4
Dulaglutide Researching Cardiovascular Events With a Weekly
Incretin in Diabetes (REWIND)
4
Liraglutide Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER)
4
Lixisenatide Evaluation of Lixisenatide in Acute Coronary Syndrome
(ELIXA)
4
Semaglutide Trial to Evaluate Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects With Type 2
Diabetes (SUSTAIN-6)
4
Insulin
Insulin degludec A Trial Comparing Cardiovascular Safety of Insulin
Degludec Versus Insulin Glargine in Patients With
Type 2 Diabetes at High Risk of Cardiovascular
Events (DEVOTE)
4
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(DPP-IV) inhibitors, GLP-1RAs and SGLT-2
inhibitors. These trials have informed our
approach as to which glucose-lowering medi-
cations may be safe in the context of T2DM and
CVD.
Which Glucose-Lowering Medications
Offer CV Protection?
DPP-IV inhibitors Collectively, these appear to
have a neutral effect on CV outcomes (Table 2).
Table 1 continued
Drug class Cardiovascular outcome trial Completed Ongoing
Insulin glargine Outcome Reduction with an Initial Glargine
Intervention (ORIGIN)
4
SGLT-2 inhibitor
Canagliflozin Canagliflozin Cardiovascular Assessment Study
(CANVAS)
4
Evaluation of the Effects of Canagliflozin on Renal and
Cardiovascular Outcomes in Participants With
Diabetic Nephropathy (CREDENCE)
4
Dapagliflozin Multicenter trial to evaluate the effect of dapagliflozin on
the incidence of cardiovascular events (DECLARE-
TIMI 58)
4
A Study to Evaluate the Effect of Dapagliflozin on Renal
Outcomes and Cardiovascular Mortality in Patients
With Chronic Kidney Disease (DAPA-CKD)
4
DAPA-HF (Study to Evaluate the Effect of
Dapagliflozin on the Incidence of Worsening Heart
Failure or Cardiovascular Death in Patients With
Chronic Heart Failure)
4
Empagliflozin Empagliflozin Cardiovascular Outcome Event Trial in
Type 2 Diabetes Mellitus Patients (EMPA-REG
OUTCOME)
4
Empagliflozin Outcome Trial in Patients With Chronic
Heart Failure With Preserved Ejection Fraction
(EMPEROR-Preserved)
4
Empagliflozin Outcome Trial in Patients With Chronic
Heart Failure with Reduced Ejection Fraction
(EMPEROR-Reduced)
4
Ertugliflozin Cardiovascular Outcomes Following Ertugliflozin
Treatment in Type 2 Diabetes Mellitus Participants
With Vascular Disease (VERTIS CV)
4
TZD
Pioglitazone Insulin Resistance Intervention After Stroke (IRIS) 4
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Table 2 Summary of DPP-IV inhibitors CVOTs
DPP-IV inhibitors
TGA-approved Reimbursed CVOT CV effect
Alogliptin [41, 42]
(Nesina)
4 EXAMINE (n = 5380)
High CV risk population
ACS requiring hospitalisation within 15–90 days
before randomisation
Primary end point: 3-point MACE
Non-inferiority design
Alogliptin vs. PBO
Neutral for MACE
HR 0.96 (95% CI\ 1.16);
p = 0.32
Linagliptin [30, 61]
(Trajenta)
4 CAROLINA (n = 6033) [29]
High risk CV and/or CKD population
Established CVD or increased risk of CVD
Primary end point: 3-point MACE
Non-inferiority design
Linagliptin vs. glimepiride
Not yet published
CARMELINA (n = 6979) [61]
High CV risk population
Existing CKD, established CVD or both
Primary end point: 3-point MACE
Non-inferiority design
Linagliptin vs.PBO
Neutral for MACE
HR 1.02 (95% CI
0.89–1.17); p\ 0 .001
Saxagliptin [39, 40]
(Onglyza)
4 SAVOR-TIMI (n=16,492)
High CV risk population
History of established CVD or multiple risk
factors for vascular disease
Primary end point: 3-point MACE
Superiority and non-inferiority design
Saxagliptin vs. PBO
Neutral for MACE
HR 1.0 (95% CI 0.89–1.12);
p = 0.99
Sitagliptin [60]
(Januvia)
4 TECOS (n = 14,671)
High CV risk population
Pre-existing CVD
Primary end point: 4-point MACE
Superiority and non-inferiority design
Sitagliptin vs.PBO
Neutral for MACE
HR 0.98 (95% CI
0.88–1.09); p\ 0.001
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None of the trials demonstrated an increase in
the primary composite end point of major
adverse cardiovascular events (MACE), which
included CV death, nonfatal MI, nonfatal stroke
with or without hospitalisation for unsta-
ble angina. There was a very small absolute
increase in cases of hospitalisation for heart
failure (0.7%) associated with the use of sax-
agliptin [39]. The increase in risk was highest in
patients at the highest absolute risk of heart
failure, i.e., those with established CVD or
multiple CVD risk factors [40]. A similar trend
was seen with alogliptin but not with the other
DPP-IV inhibitors [41, 42]. Overall, DPP-IV
inhibitors satisfied the regulatory CV safety
criteria for T2DM but appear to have no positive
impact on CV outcomes.
GLP-1RAs CVOT data are available for three
of the five GLP-1RAs approved in Australia
(Table 3). While not yet registered in Australia,
semaglutide also has published CV data [43].
The SUSTAIN-6 study reported a protective
effect on 3-point MACE, driven by a significant
reduction in nonfatal stroke [HR 0.61; (95% CI
0.38–0.99; p = 0.04)] and a nonsignificant
reduction in nonfatal MI [HR: 0.74; (95% CI
0.51–1.08; p = 0.12)]. No difference in the risk
of CV death was noted [43]. In contrast, lixise-
natide (ELIXA study) had a neutral effect on CV
outcomes [44], whereas the EXSCEL study
assessing the once-weekly exenatide prepara-
tion just failed to reach significance for CV
benefit with a 9% reduction in events (CI
0.83–1.00; p = 0.06) although a significant
reduction in cardiovascular mortality was
observed (Table 3) [45]. With liraglutide in the
LEADER study, fewer patients experienced CV-
related death, nonfatal MI or nonfatal stroke
compared with placebo: 13% (608 of 4668
patients) vs. 14.9% (694 of 4672 patients),
respectively (Table 3) [46]. The CVOT of
dulaglutide is yet to be published [47], although
the full data set is anticipated in 2019 [48].
The heterogenous effects on MACE within
this drug class may reflect differences in the
patient populations and designs of the CVOTs
as well as being potentially related to the phar-
macokinetic and structural differences between
the individual GLP-1RAs. Nevertheless, CV
safety for all the approved agents in this class
has been demonstrated in high-risk T2DM
patients [43–46]. In terms of safety and tolera-
bility, transient nausea and vomiting are com-
mon side effects among patients initiated on
GLP-1RAs yet are usually self-limiting with the
longer acting agents. Retinopathy was seen in
small numbers with semaglutide in cardiac
safety trials [43].
SGLT-2 inhibitors Three out of four TGA-ap-
proved agents in this class have CVOT data
(Table 4). Both canagliflozin and empagliflozin
demonstrated a CV benefit in terms of reducing
the primary end point of MACE, while dapa-
gliflozin was found to have a non-significant
reduction in this end point [49–51]. Ertugli-
flozin is yet to report CV outcome data
(Table 1). In the EMPA-REG OUTCOME study,
participants had established CVD (76% with
coronary artery disease; 47% with a history of
MI). The primary composite end point of death
from CV causes, nonfatal MI or nonfatal stroke
occurred in 10.5% (490 of 4687) receiving
empagliflozin (pooled doses of 10 mg and
25 mg) vs. 12.1% (282 of 2333) in the placebo
group, translating into a 14% relative risk
reduction in these events (Table 4). This reduc-
tion was primarily driven by a 38% relative risk
reduction in CV-related death [50].
Table 2 continued
DPP-IV inhibitors
TGA-approved Reimbursed CVOT CV effect
Vildagliptin (Galvus) 4 NO CVOT reported Unknown
3-point MACE: CI confidence interval; CV death, nonfatal MI or nonfatal stroke; 4-point MACE: CV death, nonfatal MI,
nonfatal stroke or hospitalisation for unstable angina; ACS acute coronary syndrome, CVD cardiovascular disease, HF heart
failure, HR hazard ratio, MACE major adverse CV effect, PBO placebo
Diabetes Ther
Table 3 Summary of GLP-1RA CVOTs
GLP-1RAs
TGA-
approved
Reimbursed CVOT CV effect
Dulaglutide
[47]
(Trulicity)
4 REWIND (n = 9901)
High CV risk population
Prior CV event, evidence of CVD or C 2 CV risk
factors
Primary end point: 3-point MACE
Dulaglutide vs. PBO
Just published
Exenatide BD
(Byetta)
4 NO CVOT reported Unknown
Exenatide QW
[45]
(Bydureon)
4 EXSCEL (n = 14,752)
High CV risk population
Pre-existing CVD
Primary end point: 3-point MACE
Non-inferiority design
Exenatide QW vs. PBO
Neutral for MACE
HR 0.91 (95% CI 0.83–1.00)
p\ 0.001 for noninferiority
Liraglutide
[46]
(Victoza)
7 LEADER (n = 9340)
High CV risk population
Pre-existing CVD; kidney disease; HF; or C 1 CV risk
factor
Primary end point: 3-point MACE
Superiority and non-inferiority design
Liraglutide vs. PBO
Benefit for MACE
HR 0.87 (95% CI 0.78–0.97)
p\ 0.001 for noninferiority,
p = 0.01 for superiority
Lixisenatide
[44]
(Lyxumia)
7 ELIXA (n = 6068)
High CV risk population
Pre-existing CVD
Primary end point: 4-point MACE
Superiority and non-inferiority design
Lixisenatide vs. PBO
Neutral for MACE
HR 1.02 (95% CI 0.89–1.17)
p\ 0.001 for noninferiority
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Although no longer government-reimbursed
in Australia, canagliflozin also led to a 14%
reduction in MACE compared with placebo in
the CANVAS programme study (Table 4) [49].
The DECLARE-TIMI 58 study supported the CV
safety of dapagliflozin in patients with T2DM
and established CVD or those with T2DM and
CV risk factors (differing from the more
homogenous EMPA-REG OUTCOME cohort)
and, unlike canagliflozin and empagliflozin,
resulted in a non-significant reduction in the
co-primary end point of MACE (Table 4) [51].
Dapagliflozin did result in a lower rate of CV
death or hospitalisation for heart failure vs.
placebo (4.9% vs. 5.8%, respectively; p = 0.005),
principally driven by a reduction in admission
for heart failure [51]. A meta-analysis of these
major trials released, at the same time as
DECLARE-TIMI 58 concluded that ‘‘SGLT-2
inhibitors have moderate benefits on
atherosclerotic MACE that seem confined to
patients with established atherosclerotic CVD.
However, they have robust benefits on reducing
hospitalisation for heart failure and progression
of renal disease regardless of existing
atherosclerotic CVD or a history of heart fail-
ure’’ [52].
Aside from CV safety, it is important to note
that SGLT-2 inhibitors as a class have shown an
increased risk of mycotic genital infections and
rarely euglycaemic diabetic ketoacidosis
[49–51]. The class generally has low rates of
hypoglycaemia unless prescribed in conjunc-
tion with sulphonylureas or insulin. The risk
can be minimised through appropriate patient
education and monitoring, such as temporarily
ceasing the medication when a patient has an
intercurrent illness or dehydration or to stop
the medication 3 days before elective surgery/
procedures.
To summarise, unlike DPP-IV inhibitors,
specific agents in the GLP-1RAs and SGLT-2
inhibitor classes have been found to confer CV
benefits in variable populations of T2DM
patients with established CVD or who are at
high risk of a CV event.
SGLT-2 Inhibitors or GLP-1RAs for At-Risk
CV Individuals with T2DM?
With their demonstrable CV safety, combined
with their favourable effects on weight and low
potential of hypoglycaemia, the recent ADA/
EASD guidelines have recommended GLP-1RAs
and SGLT-2 inhibitors as preferred treatment
Table 3 continued
GLP-1RAs
TGA-
approved
Reimbursed CVOT CV effect
Semaglutidea
[43]
4 SUSTAIN-6 (n = 3297)
High CV risk population
Established CVD, chronic heart failure or CKD
C stage 3 or C 60 years of age with at least one CV
risk factor
Primary end point
Non-inferiority design
Semaglutide vs.PBO
Benefit for MACE
HR 0.74 (95% CI 0.58–0.95)
p\ 0.001 for noninferiority
BD twice daily, CKD chronic kidney disease, HR hazard ratio, MACE major adverse CV events, PBO placebo, QW once
weekly
a Not available as of March 2019, pending TGA approval
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options in addition to metformin for those with
established CVD (e.g., patients who had expe-
rienced an MI or stroke or had undergone a
revascularisation procedure) [30]. In those
patients with T2DM and established CVD with
co-existing heart failure, or those with T2DM
and CKD (with or without CVD), SGLT-2 inhi-
bitors are considered the most appropriate
choice unless contraindicated, in which case
GLP-1RAs with proven CV benefits are recom-
mended [34, 53]. It is worth noting that there
are limited data highlighting the glycaemic
benefit of combining SGLT-2 inhibitors and
GLP-1RA therapies [54, 55]; moreover, the
impact of such a combination on CV outcomes
is unknown. From an Australian government
reimbursement perspective, such combined use
is not approved for subsidy at the present time.
Table 4 Summary of SGLT-2 inhibitor CVOTs
SGLT-2 inhibitors
TGA-approved Reimbursed CVOT CV effect
Canagliflozin [49]
(Invokana)
7 CANVAS programme (n = 9901)
High CV risk population
Prior CV event, evidence of CVD or
C 2 CV risk factors
Primary end point: 3-point MACE
Canagliflozin vs. PBO
Superiority and non-inferiority design
Benefit for MACE
Primary end point MACE
HR: 0.86 (95% CI 0.75–0.97)
p\ 0.001 for noninferiority
p = 0.02 for superiority
Dapagliflozin [51]
(Forxiga)
4 DECLARE-TIMI 58 (n = 17,160)
High CV risk population
History of established CVD or
multiple CVD risk factors
Co primary end points
1. 3-point MACE
2. Composite of CV death or
hospitalisation for heart failure
Dapagliflozin vs. PBO
Neutral for MACE
HR: 0.93 (95% CI 0.84–1.03); p = 0.17
Benefit for composite of CV death or
hospitalisation for heart failure
HR 0.83; (95% CI 0.73–0.95); p = 0.005
for superiority
Empagliflozin [50]
(Jardiance)
4 EMPA-REG OUTCOME (n = 7020)
High CV risk population
Pre-existing CVD
Primary end point: 3-point MACE
Empagliflozin vs. PBO
Superiority and non-inferiority design
Benefit for MACE
HR 0.86 (95% CI 0.74–0.99)
p = 0.04 for superiority
Ertugliflozin
(Steglatro)
4 NO CVOT reported Unknown
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NAVIGATING COMMON
AND COMPLICATED CASE
SCENARIOS IN T2DM: EXPERT
PERSPECTIVES
So how should primary practitioners interpret
the CVOT data and recent guidelines to inform
management of T2DM in primary practice? As
informative as these guidelines are, a major gap
is understanding how to treat T2DM with
multiple CV risk factors but without established
CVD. To address this, a local expert committee
that included primary practitioners, a cardiolo-
gist and an endocrinologist was convened to
identify and discuss case studies of T2DM
patients commonly seen in clinical practice
who could be stratified according to high,
moderate and low CV risk as well as by addi-
tional complications such as the presence of
CKD. The key objective was to provide a clinical
narrative alongside an algorithm (Fig. 1) that
goes beyond glucose-lowering to help guide the
treatment decision-making process for each
situation.
CASE SCENARIO: HIGH CV RISK
PATIENT
James: a 64-year-old male (ex-smoker) with a
4-year history of T2DM. This was diagnosed
when he had documented triple-vessel disease
and underwent coronary artery bypass graft
surgery 4 years ago. He recently moved into the
area and needed prescriptions. This visit pro-
vided an opportunity to review his current
medication and management.
Clinical Assessments HbA1c 7.3%
(56 mmol/mol); eGFR 60 ml/min/1.73 m2;
Fig. 1 Treatment algorithm according to CV and CKD risk
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weight 92.5 kg; height 1.83 m; BMI 27.6 kg/m2;
total cholesterol 3.9 (LDL 1.82; triglycerides 2.0;
HDL 1.03); blood pressure 130/80 mmHg; urine
ACR 7.5 mg/mmol.
Existing Medications Aspirin 100 mg once
daily; insulin glargine (40 U) and insulin aspart
(6 U at his main meal); rosuvastatin 10 mg once
daily; perindopril 5 mg once daily.
Clinical Considerations for James
James has presented with T2DM with estab-
lished CVD, which significantly increases his
immediate risk of heart failure several-fold as
well as premature mortality [56]. Diabetes
management needs to focus on optimising ways
to reduce these risks. He also has microalbu-
minuria, which contributes to a greater CV
event rate.
Primary Considerations To prevent future risk
of CVD-associated death and heart failure. To
achieve an appropriate HbA1c target (\7%;
53 mmol/mol) and optimise his glucose man-
agement to prevent the progression of
microalbuminuria and renal complications
without increasing hypoglycaemia.
How to Manage? To consider where change in
therapy may provide additional benefit, e.g.,
consideration should be focussed on the estab-
lished CV benefit from newer glucose-lowering
agents as well as optimising blood pressure
control to further lower risk of heart failure [57].
Which Glucose-Lowering Agent? An agent that
may optimise glycaemia, has a low hypogly-
caemic profile and a low-to-acceptable clinical
risk with proven CVD risk reduction in a patient
such as James with a high risk of a CV event.
Based on current evidence, an SGLT-2 inhibitor
(dapagliflozin, empagliflozin) or GLP-1RA (li-
raglutide) may be appropriate alternative
options as they have demonstrated CV benefits.
To note, in clinical trials with patients with a
similar presentation, empagliflozin showed a
CV mortality benefit while both empagliflozin
and dapagliflozin reduced HF hospitalisation
[50, 51]. When selecting SGLT-2 inhibitors,
baseline eGFR and the need for ongoing moni-
toring need to be carefully considered. Of note,
dapagliflozin is not indicated for patients with
an eGFR\ 60 ml/min/1.73 m2, while empagli-
flozin is not appropriate for patients with an
eGFR\ 45 ml/min/1.73 m2.
Other Considerations To consider patient
profile (lifestyle/adherence), patient preference
(oral versus injectable therapy) as well as cost
implications (reimbursement criteria) and
specific side effect profiles (risks for genitouri-
nary infections).
Following an informed discussion with
James and the fact that he is at risk of heart
failure and CV death, he expressed a preference
for an oral medication. An SGLT-2 inhibitor was
therefore prescribed in addition to his existing
glucose-lowering medications, and we ceased
his prandial (rapid-acting) insulin. He was
instructed to monitor his blood glucose and
report any hypoglycaemia. The perindopril was
increased to 10 mg daily.
Review
There was no reported hypoglycaemia after an
initial monthly review, and then after
3 months, James presented to review his blood
investigation result. His HbA1c was now at 6.8%
(51 mmol/mol), and his weight had dropped to
90.5 kg. He was happy as he was able to cease
his meal-time insulin. Home-monitoring of
blood pressure showed a reduction to 110/70.
He also felt motivated to make some lifestyle
changes and had started to do more daily
walking.
CASE SCENARIO: MODERATE CV
RISK PATIENT
Chris, a 59-year-old male non-smoker with a
10-year history of T2DM and prior diagnosis of
hypertension, presented to his primary practi-
tioner for a routine visit, which provided an
opportunity to review his current medication
and management of T2DM.
Clinical Assessments HbA1c 7.6%
(60 mmol/mol); eGFR 61 ml/min/1.73 m2;
weight 101.4 kg; height 1.78 m; BMI 32.0 kg/
m2; total cholesterol 3.8 (LDL 1.99; triglycerides
0.7; HDL 1.11); blood pressure 145/90 mmHg.
Urine ACR\2.5 mg/mmol.
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Existing Medications Atorvastatin 10 mg; sita-
gliptin/metformin 50/850 mg BD; ramipril 5 mg
once daily.
Clinical Considerations for Chris
While Chris has not presented with established
CVD, he has several high-risk factors that pre-
dispose him to future risk of CVD. The question
arises as to how to modify CV risk in a patient
like Chris.
Primary Considerations To optimise glycaemic
control for microvascular risk reduction and
address any weight issues by optimally assisting
with weight loss.
How to Manage? Review self-management
and lifestyle modification to assist with weight
loss and improved glycaemia. Consider the
addition of a glucose-lowering agent with pro-
ven CVD safety or positive CVD benefit that
also has weight-loss potential.
Which Glucose-Lowering Agent? Based on new
research and guidelines [30, 34, 53, 57], an
SGLT-2 inhibitor (oral once-daily dapagliflozin,
empagliflozin) or a GLP-1RA (once-daily
liraglutide, once-weekly dulaglutide) is an
appropriate add-on therapy to Chris’s current
standard-of-care treatment. When selecting
SGLT-2 inhibitors, baseline eGFR and the need
for ongoing monitoring need to be carefully
considered and the risk of euglycaemic diabetes
ketoacidosis and uncommon risks such as mild
diuresis and mycotic genital infections dis-
cussed. When selecting a GLP-1RA, the fre-
quency of injections may alter choice.
Other Considerations To consider patient
profile (lifestyle/adherence), patient preference
(oral versus injectable therapy) as well as cost
implications (reimbursement criteria).
Following an informed discussion with
Chris, he expressed preference for an oral, daily
medication (dapagliflozin, empagliflozin) as he
felt he may forget taking an injection once a
week (exenatide QW; dulaglutide). He was not
prepared to be out of pocket for the once-daily
GLP-1RA option (liraglutide) but was open to
using a weekly injection in the future. An SGLT-
2 inhibitor was therefore prescribed. In addi-
tion, his existing medications were optimised
with the dose of sitagliptin/metformin
increased to 50/1000 mg BD. The dose of rami-
pril was also increased to 10 mg and it was rec-
ommended to be taken at night.
Review
After 3 months, Chris presented for review. He
felt happy as he had managed to get his weight
down to below 100 kg. This has spurred him on
to set a weight goal of 90 kg. His HbA1c was now
7.1% (54 mmol/mol) and he had tolerated the
SGLT-2 inhibitor well, with some manageable
increased urinary frequency. As he was tolerat-
ing the SGLT-2 inhibitor, for cost reasons he was
switched to a combination SGLT-2 inhibitor
and DPP-IV inhibitor and continued on
metformin.
CASE SCENARIO: LOW CV RISK
PATIENT
Gabrielle, a 56-year old female non-smoker with
a 7-year history of T2DM, presented to her pri-
mary practitioner for a routine visit, which
provided an opportunity to review her current
medication and management of T2DM.
Clinical Assessments HbA1c 7.2%
(55 mmol/mol); eGFR 90 ml/min/1.73 m2;
weight 78 kg; height 1.66 m; BMI 28.3 kg/m2;
total cholesterol 5.8 (LDL 3.2; triglycerides 1.4;
HDL 1.2); blood pressure 110/70 mmHg; ACR
normal. Absolute CVD risk score reveals Gab-
rielle to have a low risk of CV (6%).
Clinical Considerations for Gabrielle
In a younger patient with T2DM there is a need
to focus on long-term complication prevention.
‘‘Tight’’ glycaemic control may assist in reduc-
ing microvascular risk, but macrovascular risk
reduction is equally important. Women with
diabetes may in fact have higher long-term risks
of ischaemic heart disease compared with aged-
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matched males [58] and a 50% greater risk of a
CV-related fatal outcome [59]. Specific attention
to modifiable risk factor reduction is therefore
imperative.
Existing Medications Metformin 850 mg BD.
Primary Consideration To proactively manage
long-term modifiable CV risk while managing
glycaemia.
How to Manage? To consider individualising
‘‘tight’ glycaemic management without
increasing hypoglycaemia risk and addressing
lipid control.
Other Considerations To consider patient
profile (lifestyle/adherence), patient preference
(formulation) as well as cost implications (re-
imbursement criteria).
Following an informed discussion and rein-
forcing the importance of lifestyle modifica-
tions, Gabrielle agreed the first step would be to
optimise her current medications to improve
her glycaemic and lipid levels. We should be
concerned about her long-term CVD risk as this
is often underestimated in women. Her CVD
risk should continue to be monitored and will
fall into a high-risk group as she turns 60. For
the time being, changes to her glucose-lowering
medications are not considered necessary and
she will continue to be monitored.
Review
After 3 months, Gabrielle presented for review.
She was commenced on a DPP-IV inhibitor and
achieved a reduction of HbA1c to 6.9%
(52 mmol/mol). By maintaining a healthier
lifestyle, she has also experienced some 2 kg
weight loss and has understood the importance
of assessing her cholesterol on an ongoing basis.
CONCLUSIONS
Individuals with T2DM and who are at an
increased risk of CV and/or CKD can be opti-
mally managed through the addition of selec-
tive SGLT-2 inhibitors or GLP-1RAs to their
existing standard of care. Treatment choice
should be guided by clinical criteria, including
the level of CV or CKD risk, as well as individual
goals, patient preference for oral or
injectable therapies and cost implications of a
given treatment for the patient.
ACKNOWLEDGEMENTS
Funding. This review was funded by Boeh-
ringer Ingelheim Australia. All authors had full
access to the articles reviewed in this manu-
script and take complete responsibility for the
integrity and accuracy of this manuscript. No
rapid service fee was received by the journal for
the publication of this article.
Medical Writing Assistance. Editorial assis-
tance was provided by Dr. Beejal Vyas-Price of
McCann Healthcare Australia. Support for this
assistance was funded by Boehringer Ingelheim
Australia.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published. The
authors would like to thank Dr Jo-Anne Manski-
Nankervis for review and comments throughout
the development of this manuscript.
Disclosures. Gary Deed has received hono-
raria, speaker fees, consultancy fees, is a mem-
ber of advisory boards or has appeared on expert
panels for: Astra Zeneca, Boehringer Ingelheim,
Bristol Myers Squibb, Inova, Lilly, Merck Sharp
and Dohm, Novartis, Novo-Nordisk, National
Prescriber Service and Sanofi. John Atherton has
previously received honoraria, travel sponsor-
ship or consultancy payment from AstraZeneca,
Bayer, Boehringer Ingelheim, Bristol-Myers
Squibb, Eli Lilly, Menarini, Novartis, Otsuka,
Servier and Vifor Pharma. Michael d’Emden has
received honoraria for attendance at national
advisory boards, presentations and/or support
to attend international meetings from Boeh-
ringer Ingelheim, Eli Lilly, Astra Zeneca,
Novartis, Abbott, Novo Nordisk, Servier and
Bayer. Roy Rasalam has received speaker hono-
rarium from Eli Lilly. Anita Sharma has nothing
Diabetes Ther
to disclose. Andrew Sindone has received
honoraria, speaker fees and consultancy fees, is
a member of advisory boards or expert panels
for: Alphapharm, Aspen, Astra Zeneca, Bayer,
Biotronik, Boehringer Ingelheim, Bristol Myers
Squibb, HealthEd, Jansen Cilag, Menarini,
Merck Sharp and Dohm, Mylan, Novartis,
Otsuka, Pfizer, Roche, Sanofi, Servier and Vifor.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Data Availability. Data sharing is not
applicable to this article as no datasets were
generated or analysed during the current study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. International Diabetes Federation. IDF diabetes
atlas, 8th edn. Brussels: International Diabetes
Federation; 2017. http://www.diabetesatlas.org.
Accessed 4 July 2019.
2. Shaw J, Thomas M, Magliano D. The dark heart of
type 2 diabetes. Baker Heart and Diabetes Institute.
2017. https://www.baker.edu.au/-/media/
documents/impact/Baker-Institute-The-dark-heart-
of-type-2-diabetes.ashx?la=en9. Accessed 13 May
2019.
3. Britt H, Miller GC, Henderson J, et al. General
practice activity in Australia 2015–16. General
practice series no. 40. Sydney: Sydney University
Press; 2016. http://purl.library.usyd.edu.au/sup/
9781743325131. Accessed 13 May 2019.
4. Newton P, Davidson PM, Reidet CM, et al. Acute
heart failure admissions in New South Wales and
the Australian Capital Territory: the NSW HF
Snapshot Study. Med J Aust. 2016;204(113):e1–8.
5. Caughey GE, Vitry AI, Gilbert AL, Roughead EE.
Prevalence of comorbidity of chronic diseases in
Australia. BMC Public Health. 2008;8:221.
6. Australian Institute of Health and Welfare. Deaths
among people with diabetes in Australia,
2009–2014. Cat. no. CVD 79. Canberra: AIHW;
2017.
7. Emerging Risk Factors Collaboration, Sarwar N, Gao
P, et al. Diabetes mellitus, fasting blood glucose
concentration, and risk of vascular disease: a col-
laborative meta-analysis of 102 prospective studies.
Lancet. 2010;375(9733):2215–22.
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K,
Laakso M. Mortality from coronary heart disease in
subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarc-
tion. N Engl J Med. 1998;339(4):229–34.
9. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris
I. Is diabetes a coronary risk equivalent? Systematic
review and meta-analysis. Diabet Med.
2009;26(2):142–8.
10. Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Dia-
betes and prior coronary heart disease are not nec-
essarily risk equivalent for future coronary heart
disease events. J Gen Intern Med.
2016;31(4):387–93.
11. Diabetes: the silent pandemic and its impact on
Australia. Baker Heart and Diabetes Institute. 2012.
https://baker.edu.au/impact/advocacy/the-silent-
pandemic. Accessed 13 May 2019.
12. National Vascular Disease Prevention Alliance.
Guidelines for the management of absolute car-
diovascular disease risk. 2012. Available at: https://
informme.org.au/en/Guidelines/Guidelines-for-
the-assessment-and-management-of-absolute-CVD-
risk. Accessed 4 July 2019.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil
HA. 10-Year follow-up of intensive glucose control
in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
14. Nathan DM, Cleary PA, Backlund JY, et al. Intensive
diabetes treatment and cardiovascular disease in
patients with type 1 diabetes. N Engl J Med.
2005;22:2643–53.
15. Patel A, MacMahon S, Chalmers J, ADVANCE Col-
laborative Group, et al. Intensive blood glucose
control and vascular outcomes in patients with type
2 diabetes. N Engl J Med. 2008;358:2560–72.
Diabetes Ther
16. Action to Control Cardiovascular Risk in Diabetes
Study Group, Gerstein HC, Miller ME, et al. Effects
of intensive glucose lowering in type 2 diabetes.
N Engl J Med. 2008;358(24):2545–59.
17. Duckworth W, Abraira C, Moritz T, et al. Glucose
control and vascular complications in veterans with
type 2 diabetes. N Engl J Med. 2009;360:129–39.
18. Control Group, Turnbull FM, Abraira C, et al.
Intensive glucose control and macrovascular out-
comes in type 2 diabetes. Diabetologia.
2009;52:2288–98.
19. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of
intensive control of glucose on cardiovascular out-
comes and death in patients with diabetes mellitus:
a meta-analysis of randomised controlled trials.
Lancet. 2009;373:1765–72.
20. Gunton JE, Cheung NW, Davis TME, Zoungas S,
Colagiuri S. A new blood glucose management
algorithm for type 2 diabetes. A position statement
of the Australian Diabetes Society. Med J Aust.
2014;201:650–3.
21. Stratton IM, Adler AI, Neil HAW, et al. Association
of glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ.
2000;321:405–12.
22. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin
on cardiovascular disease: a meta-analysis of ran-
domised trials among people with type 2 diabetes.
Diabetologia. 2017;60(9):1620–9.
23. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology
and therapeutic implications of current drugs for
type 2 diabetes mellitus. Nat Rev Endocrinol.
2016;12:566–92.
24. Varvaki Rados DV, Catani Pinto L, Reck Remonti L,
Bauermann Leita˜o C, Gross JL. The association
between sulfonylurea use and all-cause and cardio-
vascular mortality: a meta-analysis with trial
sequential analysis of randomized clinical trials.
PLOS Med. 2016;13(4):e1001992. https://doi.org/
10.1371/journal.pmed.1001992.
25. Gangji AS, Cukierman T, Gerstein HC, Goldsmith
CH, Clase CM. A systematic review and meta-anal-
ysis of hypoglycemia and cardiovascular events: a
comparison of glyburide with other secretagogues
and with insulin. Diabetes Care. 2007;30:389–94.
26. Bain S, Druyts E, Balijepalli C, et al. Cardiovascular
events and all-cause mortality associated with sul-
fonylureas compared with other antihypergly-
caemic drugs: a Bayesian meta-analysis of survival
data. Diabetes Obes Metab. 2017;19(3):329–35.
27. Pladevall M, Riera-Guardia N, Margulis AV, Varas-
Lorenzo C, Calingaert B, Perez-Gutthann S. Car-
diovascular risk associated with the use of glita-
zones, metformin and sufonylureas: meta-analysis
of published observational studies. BMC Cardiovasc
Disord. 2016;16:14.
28. Powell WR, Christiansen CL, Miller DR. Meta-
analysis of sulfonylurea therapy on long-term risk
of mortality and cardiovascular events compared to
other oral glucose-lowering treatments. Diabetes
Ther. 2018;9(4):1431–40.
29. Phung OJ, Schwartzman E, Allen RW, Engel SS,
Rajpathak SN. Sulphonylureas and risk of cardio-
vascular disease: systematic review and meta-anal-
ysis. Diabet Med. 2013;30(10):1160–71.
30. Press release. Boehringer Ingelheim and Lilly
announce the CAROLINA cardiovascular outcome
trial of Tradjenta met its primary endpoint of non-
inferiority compared with glimepiride. https://
www.boehringer-ingelheim.us/press-release/
boehringer-ingelheim-and-lilly-announce-carolina-
cardiovascular-outcome-trial. Accessed 15 Feb 2019.
31. Davies MJ, D’Alessio DA, Fradkin J, et al. Manage-
ment of hyperglycemia in type 2 diabetes, 2018. A
consensus report by the American Diabetes Associ-
ation (ADA) and the European Association for the
Study of Diabetes (EASD). Diabetes Care.
2018;41(12):2669–701.
32. U.S. Food and Drug Administration. Guidance for
industry: diabetes mellitus devaluating cardiovas-
cular risk in new antidiabetic therapies to treat type
2 diabetes. 2008. https://www.fda.gov/downloads/
Drugs/Guidances/ucm071627.pdf. Accessed 20 Aug
2018.
33. European Medicines Agency. Guideline on clinical
investigation of medicinal products in the treat-
ment or prevention of diabetes mellitus. 2012.
http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2012/06/
WC500129256.pdf. Accessed 20 Aug 2018.
34. Cefalu WT, et al. Cardiovascular outcomes trials in
type 2 diabetes: where do we go from here? Diabetes
Care. 2018;41:14–31.
35. American Diabetes Association. 9. Cardiovascular
disease and risk management: standards of medical
care in diabetes. 2018. Diabetes Care.
2018;41(Suppl. 1):S86–104.
36. Diabetes Canada. Clinical practice guidelines. 2018.
http://guidelines.diabetes.ca/cpg. Accessed 4 July
2019.
Diabetes Ther
37. Mancini GR, Hegele RA, Leiter LA. 2018 clinical
practice guidelines; dyslipidemia. Can J Diabetes.
2018;42:S178–85.
38. NHFA CSANZ Atrial Fibrillation Guideline Working
Group, Brieger D, Amerena J, et al. National Heart
Foundation of Australia and the Cardiac Society of
Australia and New Zealand: Australian clinical
guidelines for the diagnosis and management of
atrial fibrillation 2018. Heart Lung Circ.
2018;27(10):1209–66.
39. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin
and cardiovascular outcomes in patients with type
2 diabetes mellitus. N Engl J Med.
2013;369:1317–26.
40. Scirica B, Braunwald E, Raz I, et al. Heart failure,
saxagliptin, and diabetes mellitus: observations
from the SAVOR-TIMI 53 randomized trial. Circu-
lation. 2014;130:1579–88.
41. White WB, Cannon CP, Heller SR, et al. Alogliptin
after acute coronary syndrome in patients with type
2 diabetes. N Engl J Med. 2013;369:1327–35.
42. Zannad F, Cannon CP, Cushman WC, et al. Heart
failure and mortality outcomes in patients with
type 2 diabetes taking alogliptin versus placebo in
EXAMINE: a multicentre, randomised, double-
blind trial. Lancet. 2015;385:2067–76.
43. Marso SP, Bain SC, Consoli A, et al. Semaglutide
and cardiovascular outcomes in patients with type
2 diabetes. N Engl J Med. 2016;375:1834–44.
44. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in
patients with type 2 diabetes and acute coronary
syndrome. N Engl J Med. 2015;373:2247–57.
45. Holman RR, Bethel MA, Mentz RJ, et al. Effects of
once-weekly exenatide on cardiovascular outcomes
in type 2 diabetes. N Engl J Med. 2017;377:1228–39.
46. Marso SP, Daniels GH, Brown-Frandsen K, et al.
Liraglutide and cardiovascular outcomes in type 2
diabetes. N Engl J Med. 2016;375:311–22.
47. Gerstein HC, Colhoun HM, Dagenais GR, et al.
Design and baseline characteristics of participants
in the Researching cardiovascular Events with a
Weekly INcretin in Diabetes (REWIND) trial on the
cardiovascular effects of dulaglutide. Diabetes Obes
Metab. 2018;20(1):42–9.
48. Press Release. Trulicity (dulaglutide) demonstrates
superiority in reduction of cardiovascular events for
broad range of people with type 2 diabetes. https://
investor.lilly.com/news-releases/news-release-
details/trulicityr-dulaglutide-demonstrates-
superiority-reduction. Accessed 5 Nov 2018.
49. Neal B, Perkovic V, Mahaffey KW, et al. Canagli-
flozin and cardiovascular and renal events in type 2
diabetes. N Eng J Med. 2017;377:644–57.
50. Zinman B, Wanner C, Lachin JM, et al. Empagli-
flozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 2015;373:2117–28.
51. Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-
TIMI 58: participants’ baseline characteristics. Dia-
betes Obes Metab. 2018;20(5):1102–10.
52. Zelnicker TA, Wiviott SD, Raz I, et al. SGLT2 inhi-
bitors for primary and secondary prevention of
cardiovascular and renal outcomes in type 2 dia-
betes: a systematic review and meta-analysis of
cardiovascular outcome trials. Lancet.
2019;393(10166):31–9.
53. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC
expert consensus decision pathway on novel ther-
apies for cardiovascular risk reduction in patients
with type 2 diabetes and atherosclerotic cardiovas-
cular disease: a report of the American College of
Cardiology Task Force on Expert Consensus Deci-
sion Pathways. J Am Coll Cardiol.
2018;72(24):3200–23.
54. Frias JP, Guja C, Hardy E, et al. Exenatide once
weekly plus dapagliflozin once daily versus exe-
natide or dapagliflozin alone in patients with type 2
diabetes Inadequately controlled with metformin
monotherapy (DURATION-8): a 28 week, multi-
centre, double-blind, phase 3, randomised con-
trolled trial. Lancet Diabetes Endocrinol.
2016;4:1004–16.
55. Ludvik B, Frı´as JP, Tinahones FJ, et al. Dulaglutide
as add-on therapy to SGLT2 inhibitors in patients
with inadequately controlled type 2 diabetes
(AWARD-10): a 24-week, randomised, double-blind,
placebo-controlled trial. Lancet Diabetes Endocri-
nol. 2018;6(5):370–81.
56. Dhingra R, Vasan RS. Diabetes and the risk of heart
failure. Heart Fail Clin. 2011;8(1):125–33.
57. Atherton JJ, Sindone A, De Pasquale CG, et al.
National Heart Foundation of Australia and Cardiac
Society of Australia and New Zealand: Australian
clinical guidelines for the management of heart
failure 2018. Med J Aust. 2018;209(8):363–9.
58. McSweeney JC, Rosenfeld AG, Abel WM, et al.
Preventing and experiencing ischemic heart disease
as a woman: state of the science: a scientific state-
ment from the American Heart Association. Circu-
lation. 2016;133(13):1302–31.
59. Huxley R, Barzi F, Woodward M. Excess risk of fatal
coronary heart disease associated with diabetes in
Diabetes Ther
men and women: meta-analysis of 37 prospective
cohort studies. BMJ. 2006;332(7533):73–8.
60. Cornell JB, Bethel MA, Armstrong PW, et al. Effect
of sitagliptin on cardiovascular outcomes in type 2
diabetes. N Engl J Med. 2015;373:232–42.
61. Rosenstock J, Perkovic V, Johansen OE, et al. Effect
of linagliptin vs placebo on major cardiovascular
events in adults with type 2 diabetes and high car-
diovascular and renal risk: the CARMELINA ran-
domized clinical trial. JAMA. 2019;321(1):69–79.
Diabetes Ther
